(Q38033191)

27 August 2017

title

Role of melatonin in mood disorders and the antidepressant effects of agomelatine (English)

1 reference

27 August 2017

0 references

1 reference

2

1 reference

27 August 2017

author name string

Venkataramanujam Srinivasan

series ordinal

1

1 reference

27 August 2017

Samuel D Shillcutt

series ordinal

3

1 reference

27 August 2017

Amnon Brzezinski

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

9 August 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1503-1522

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Anxiety, depression, and cause-specific mortality: the HUNT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Depressive symptoms predict mortality in elderly subjects with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mortality in people with depressive, anxiety and alcohol use disorders in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mortality associated with major depression in a Canadian community cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Major depression: emerging therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Circadian rhythm disturbances in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Pathophysiology of depression: role of sleep and the melatonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Sleep and depression--results from psychobiological studies: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Sleep complaints and depression in an aging cohort: A prospective perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Depression and insomnia: questions of cause and effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A retinohypothalamic pathway in man: light mediation of circadian rhythms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Bright white light alleviates depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

New approaches to antidepressant drug discovery: beyond monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Melatonin receptors: localization, molecular pharmacology and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Molecular tools to study melatonin pathways and actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Role of protein kinase Calpha in melatonin signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Melatonin as a cytoskeletal modulator: implications for cell physiology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Clinical Importance of Melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The dexamethasone suppression test for melancholia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Sleep and circadian rhythms in affective patients isolated from external time cues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Depression and endogenous melatonin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Neuroendocrine aspects of primary endogenous depression. XV: Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Melatonin in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Serum melatonin and urinary 6-sulfatoxymelatonin in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Desmethylimipramine treatment increases melatonin production in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The switch process from depression to mania: relationship to drugs which alter brain amines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The switch process in manic-depressive illness. Circadian variation in time of switch and sleep and manic ratings before and after switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Melatonin suppression by light in euthymic bipolar and unipolar patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Winter depression and the phase-shift hypothesis for bright light's therapeutic effects: history, theory, and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A circadian signal of change of season in patients with seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Morning vs evening light treatment of patients with winter depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Emerging targets for antidepressant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Pharmacotherapy of bipolar depression: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Depression, sleep physiology, and antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Effects of psychiatric medications on sleep and sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Defining and measuring clinical effectiveness in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Are the dorsal and ventral hippocampus functionally distinct structures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The interaction between the internal clock and antidepressant efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine: The evidence for its place in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine in the treatment of seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Could agomelatine be the ideal antidepressant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Agomelatine in the treatment of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Sleep disturbances and depression: a challenge for antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Levels of anxiety and depression as predictors of mortality: the HUNT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

Seasonality of psychopathology and circannual melatonin rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711314

10.1517/13543784.2012.711314

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference